Super Tuesday couldn’t come any sooner for the Republican Party

On July 23, 2016, we discontinued our forums. We ask our members to please join us in our new community site, The Hartmann Report. Please note that you will have to register a new account on The Hartmann Report.

1 post / 0 new

With 419 delegates in 11 states up for grabs – a clear picture may emerge tonight of who the Republican nominee will be – most likely Mitt Romney - who is expected to take the majority of delegates and easily win 4 primaries – and should pull off a win in the swing state of Ohio, too. Looking at numbers from a new NBC/Wall Street Journal poll – Republicans desperately need this primary season to end as soon as possible. Of those polled, 40% say the primary process has created a less favorable view of the Republican Party – and Mitt Romney’s favorable rating stands at just 28% now.

Meanwhile in hypothetical contests with the Republican candidates – President Obama is polling above 50%, forecasting a landslide victory. And to top it all off – by a margin of 46% to 41% - Americans want Democrats more than Republicans to control Congress next year. The Republicans were given a chance to govern the nation in 2010 – and they squandered it by appealing to the lowest common denominators within their party – only looking out for misogynists, millionaires, and billionaires – and putting the destruction of Barack Obama ahead of fixing the economy.

So even though Super Tuesday is here and the primary season may soon be winding down – it will take a lot of fat-cat corporate cash to rehabilitate the Republican Party’s image heading into the general election.

Thom Hartmann Administrator's picture
Thom Hartmann A...
Joined:
Dec. 29, 2009 10:59 am

We Are All Pharma-Bro Suckers

"Pharma Bro" Martin Shkreli became one of the most notorious people in America for hiking the price of a rarely used life-saving drug by 4,000 percent in September of 2015.

And nearly a year later, dozens of reports are now coming out about how Mylan Pharmaceuticals hiked the price of the very common life-saving EpiPen by over 450% since Mylan bought EpiPen in 2007.

Powered by Pressflow, an open source content management system